ST. HELIER, Jersey–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVCR&src=ctag" target="_blank"gt;$NVCRlt;/agt;–Novocure (NASDAQ:NVCR) announced today that it will report financial
results for the first quarter 2019 on Thursday, May 2, 2019, before the
U.S. financial markets open. Novocure management will host a conference
call and webcast to discuss its financial results for the three months
ended March 31, 2019, at 8 a.m. EDT on Thursday, May 2, 2019.
Analysts and investors can participate in the conference call by dialing
855-442-6895 for domestic callers and 509-960-9037 for international
callers, using the conference ID 8956998. The webcast and earnings
slides presented during the webcast can be accessed live from the
Investor Relations page of Novocure’s website, www.novocure.com/investor-relations,
and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is a global oncology company working
to extend survival in some of the most aggressive forms of cancer by
developing and commercializing its innovative therapy, Tumor Treating
Fields. Tumor Treating Fields is a cancer therapy that uses electric
fields tuned to specific frequencies to disrupt solid tumor cancer cell
division. Novocure’s commercialized product is approved for the
treatment of adult patients with glioblastoma. Novocure has ongoing or
completed clinical trials investigating Tumor Treating Fields in
mesothelioma, brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and liver cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts
or statements of current condition, this press release may contain
forward-looking statements. Forward-looking statements provide
Novocure’s current expectations or forecasts of future events. These may
include statements regarding anticipated scientific progress on its
research programs, clinical trial progress, timing of clinical
milestones, development of potential products, interpretation of
clinical results, prospects for regulatory submission and approval,
manufacturing development and capabilities, market prospects for its
products, coverage, collections from third-party payers and other
statements regarding matters that are not historical facts. You may
identify some of these forward-looking statements by the use of words in
the statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 28, 2019, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.
Contacts
Media and Investors:
Ashley Cordova
acordova@novocure.com
212-767-7558